Clinical trial
A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
NCT00706030 is registered in ClinicalTrials.gov with Puma Biotechnology, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study Of HKI-272 In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
- Lead sponsor
- Puma Biotechnology, Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 29, 2008
- Completion date
- June 7, 2018
- Enrollment
- 92 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant solid tumors, breast cancer